Form 4: Arcellx Director Andrew Galligan Receives New Stock Option Grant

Arcellx, Inc. Director Andrew H. Galligan was granted 1,784 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Summary

• Andrew H. Galligan, a Director of Arcellx, Inc. (ACLX), was granted 1,784 stock options.
• The exercise price for these options is $63.68 per share.
• The options were granted on May 29, 2025, and are set to expire on May 29, 2035.
• The shares subject to the award will vest 100% on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent on Mr. Galligan's continued service as a Service Provider under the 2022 Equity Incentive Plan.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal for aligning interests and retaining talent, but it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options serves as an incentive for the director, aligning their interests with long-term shareholder value.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent transaction.

Future Outlook

The stock options are subject to a vesting schedule, with 100% vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent on continued service. The options have an expiration date of May 29, 2035.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term commitment and align interests with shareholders. This is a standard compensation mechanism.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation, widely used across industries, including biotechnology, to attract and retain talent and align executive/director interests with shareholder value.
• The vesting schedule (100% on the earlier of one year or next annual meeting) is a common structure for director equity awards, often designed to compensate for board service and encourage long-term engagement.
• The exercise price of $63.68, being the market price at the time of grant, is typical for incentive stock options.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. It also represents a minor dilution potential upon exercise.

Next Steps

• The stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, subject to continued service.
• The director may exercise these options at any time after vesting until the expiration date of May 29, 2035.

Key Dates

Recommendation

Keywords

Arcellx, ACLX, Form 4, SEC Filing, Stock Option, Director Compensation, Equity Incentive Plan, Insider Transaction, Andrew Galligan, Biotechnology, Pharmaceuticals